Protagenic Therapeutics (PTIX) AI Stock Analysis

• Market Cap: $1.00M
• Dividend Yield: N/A
• Average Volume (3M): 102.28K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.90
• Revenue Growth: N/A
• EPS Growth: 64.85%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -15.83
• Shares Outstanding: 1,927,898
• 10 Day Avg. Volume: 80,054
• 30 Day Avg. Volume: 102,276
• PEG Ratio: 3.50
• Price to Book (P/B): 33.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.97
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: -22.47
• Enterprise Value/Gross Profit: -7.49
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 27 Underperform
• Price Target: ―

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company's valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

Positive Factors

Clinical Trial Progress

Advancing clinical trials for PT00114 indicates progress in drug development, potentially leading to new revenue streams upon successful commercialization.

Innovative Therapeutic Approach

A unique therapeutic mechanism can create a competitive advantage in treating CNS disorders, enhancing market position and long-term growth prospects.

Intellectual Property Strength

Securing patents strengthens the company's intellectual property portfolio, protecting innovations and supporting long-term competitive positioning.

Negative Factors

Financial Instability

Persistent financial losses and lack of revenue highlight challenges in achieving financial stability, increasing reliance on external funding.

Negative Cash Flow

Negative cash flow from operations indicates unsustainable financial practices, potentially limiting the company's ability to fund R&D and growth.

Deteriorating Equity

Decreasing equity reflects weakening financial health, which could hinder the company's ability to invest in future growth opportunities.

Protagenic Therapeutics Business Overview & Revenue Model

Company Description

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

How the Company Makes Money

Protagenic Therapeutics primarily makes money through the development and commercialization of its neuropeptide-based therapeutics. The company seeks to generate revenue by advancing its drug candidates through clinical trials, obtaining regulatory approvals, and ultimately licensing or partnering these therapeutics with larger pharmaceutical companies for distribution and marketing. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and eventually, sales of approved therapeutics. The company's ability to secure funding through equity offerings, grants, and collaborations also plays a crucial role in supporting its research and development efforts.

Protagenic Therapeutics Financial Statement Overview

Summary

Protagenic Therapeutics is struggling financially with no revenue generation and consistent operating losses. The balance sheet reflects diminishing equity and assets, while cash flows are negative, highlighting liquidity issues and reliance on external financing. The company faces significant challenges in achieving financial stability and growth.

Income Statement

Protagenic Therapeutics has consistently reported zero revenue over the years, reflecting a lack of commercialized products. The company is incurring significant operating losses, as indicated by negative EBIT and net income figures. Given the absence of revenue growth and persistent losses, the income statement reflects weak financial performance.

Balance Sheet

The balance sheet shows a relatively low level of debt with no total debt reported in the most recent year, which is positive for financial stability. However, the company's stockholders' equity has significantly decreased over the years, indicating a deterioration in financial health. The equity ratio has decreased due to declining total assets and stockholders' equity, suggesting potential financial instability.

Cash Flow

The cash flow statement reveals negative operating cash flow, which indicates that the company is not generating enough cash from its core operations. Free cash flow is also negative, emphasizing cash constraints. The company relies heavily on financing activities to support operations, which may not be sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-50.29K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-150.86K	-50.29K	-28.22K	-30.00	0.00	-286.00
EBITDA	-20.02M	-5.47M	-4.50M	-3.42M	-4.14M	-2.55M
Net Income	-19.58M	-5.53M	-5.00M	-3.56M	-4.52M	-2.55M
Balance Sheet
Total Assets	2.14M	1.96M	4.32M	8.04M	11.06M	879.25K
Cash, Cash Equivalents and Short-Term Investments	2.72M	1.84M	4.06M	7.98M	10.37M	671.09K
Total Debt	3.16M	0.00	0.00	344.23K	318.43K	1.37M
Total Liabilities	9.70M	942.76K	655.25K	1.12M	1.12M	2.03M
Stockholders Equity	-7.56M	1.01M	3.67M	6.92M	9.94M	-1.15M
Cash Flow
Free Cash Flow	-12.09M	-4.22M	-3.85M	-2.00M	-2.80M	-1.35M
Operating Cash Flow	-12.09M	-4.22M	-3.70M	-1.99M	-2.80M	-1.35M
Investing Cash Flow	5.66M	2.80M	4.78M	1.60M	-9.91M	0.00
Financing Cash Flow	29.48M	1.96M	0.00	0.00	12.58M	1.22M

Protagenic Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTIX, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 1.26, and below the 200-day MA of 2.86, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 35.07 is Neutral, neither overbought nor oversold. The STOCH value of 54.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTIX.

Protagenic Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KALA	40 Underperform	$16.14M	-0.09	―	―	―	52.39%
ONCO	33 Underperform	$2.33M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.48M	-0.05	-168.95%	―	―	90.27%
PTIX	27 Underperform	$1.00M	-0.07	―	―	―	64.85%

Protagenic Therapeutics Corporate Events

Protagenic Therapeutics Faces Nasdaq Delisting Notice

On November 20, 2025, Protagenic Therapeutics received a notification from Nasdaq indicating non-compliance with listing rules due to insufficient stockholders’ equity and delayed filing of a quarterly report. The company plans to appeal the delisting decision and has requested a hearing, during which its stock will continue to trade on Nasdaq. However, there is no assurance that the appeal will be successful or that compliance will be regained.

Jennifer Chao Resigns from Protagenic Therapeutics Board

On November 3, 2025, Jennifer Chao resigned from the Board of Directors of Protagenic Therapeutics, Inc., with no disagreements reported between her and the company.

Protagenic Therapeutics Seeks Rescission of Share Agreement

On October 28, 2025, Protagenic Therapeutics, Inc. filed a Verified Complaint in the Delaware Chancery Court seeking rescission of the Share Exchange Agreement with Phytanix Bio, Inc., dated May 15, 2025. The company alternatively seeks damages and an order for the delivery of audited financial statements as stipulated in the agreement, potentially impacting its acquisition strategy and financial transparency obligations.